IPO Price Range: ₹85 - 90
Min Investment
₹1,44,000
IPO Size
₹41 Cr
IPO Status
Quantity in 1 Lot
1600
Max Bid allowed
1
Listing Exchange
NSE
Bid Opening Date | 28 Jun 2024 |
Bid Closing Date | 2 Jul 2024 |
Allotment Date | 3 Jul 2024 |
Issue Size | ₹41.26Cr |
Quantity in 1 lot | 1600 |
We bridge the gap between day care and tertiary care services by addressing unmet needs through a blend of modern medical science and time tested yogic wisdom for overall wellbeing of the patients.
Our technology backbone is robust and supports consistent improvements in the quality and efficiency of our service delivery.
Track record of operating and financial performance and growth.
Professional management and experienced leadership.
Investment in infrastructure, processes and clinical services delivery framework, affordability resulting in a strong value proposition for stakeholders.
Its Promoter, Dr. Pratim Sengupta, plays a key role in the company functioning and its heavily relies on his knowledge and experience in operating its business and therefore, it is critical for the companys business that its Promoter remain associated with the company.
Its expansion into new business vertical, i.e. setting up a hospital, may expose the company to new challenges and more risks.
The companys revenues are significantly dependent on its flagship Salt Lake clinic. Further, all its clinics are located in the Kolkata. Any impact on the revenues of its flagship Salt Lake clinic or any change in the economic or political circumstances of West Bengal or particularly in or around Kolkata, could materially affect its business, financial condition and results of operations.
The company is highly dependent on its healthcare professionals including doctors and nurses, and any future inability to attract/ retain such professionals will adversely affect its business, financial condition and results of operations.
Its industry is highly regulated and requires it to obtain, renew and maintain statutory and regulatory permits, accreditations, licenses and comply with applicable safety, health, environmental, labour and other governmental regulations. Any regulatory changes or violations of such rules and regulations may adversely affect its business, financial condition and results of operations.
The company incur high expenses in relation to manpower cost, infrastructure and medical maintenance and repair costs, ancillary and various pharmaceuticals items. If the company is unable to obtain favourable pricing from suppliers or negotiate compensation of its healthcare professionals effectively, it could affect its profitability. Any inability to pass on such costs to its patients, may have an adverse impact on its business, financial condition and results of operations.
There can be no assurance that the objects of the Issue will be achieved within the time frame anticipated or at all, or that the deployment of the Net Proceeds in the manner intended by it will result in any increase in the value of your investment. Further, the plan for deployment of the Net Proceeds has not been appraised by any bank or financial institution.
Its ability to provide affordable healthcare depends on the maintenance of a high volume of patients and effective capital management. Any increase in such costs could adversely affect its business, financial condition and results of operations.
The Company is yet to place orders for the equipments and machines required for its proposed multi-speciality hospital. Any delay in placing orders or procurement of such equipment, may further delay the schedule of implementation and increase the cost of commissioning the manufacturing units.
The company may experience delays in commencement of operations of its proposed hospital or the company may be unsuccessful in implementing its growth plans of expansion in a timely manner or at all, which may have an adverse effect on its business, financial condition and results of operations.
Organisation | Nephro Care India Ltd |
Headquarters | Kolkata |
Industry | Healthcare |